bis-pyridinyl benzyl ethanediamine | 1507370-20-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: bis-pyridinyl benzyl ethanediamine
• 英文别名: BC-1215；N,N'-bis[(4-pyridin-2-ylphenyl)methyl]ethane-1,2-diamine
• CAS: 1507370-20-8
• 化学式: C₂₆H₂₆N₄
• 分子量: 394.519
• InChiKey: IXEPQJQQSLMESJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  30
• 可旋转键数：
  9
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.15
• 拓扑面积：
  49.8
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为产物：
  描述：

  4-(2-吡啶基)-苯甲醛 在 甲醇 、 sodium tetrahydroborate 作用下， 以 乙醇 为溶剂， 反应 0.75h， 生成 bis-pyridinyl benzyl ethanediamine
  参考文献：
  名称：

  [EN] FBXO3 INHIBITORS
  [FR] INHIBITEURS DE FBXO-3

  摘要：

  本申请公开了苯扎托品及相关化合物及其作为FBXO-3抑制剂的应用。

  公开号：

  WO2013184202A1

文献信息

• [EN] COMPOSITIONS AND METHODS FOR TREATING RESPIRATORY INJURY OR DISEASE<br/>[FR] COMPOSITIONS ET MÉTHODES DE TRAITEMENT D'UNE LÉSION OU MALADIE RESPIRATOIRE
  申请人：UNIV PITTSBURGH

  公开号：WO2015089087A1

  公开（公告）日：2015-06-18

  A method for treating a respiratory injury or disease comprising: administering to a patient in need of treatment a pharmaceutical composition comprising a compound of general Formula I: or salt, ester, solvate, hydrate, or prodrug thereof; wherein: x is an integer from 1 to 10; A and B are each, independently, C3-7 cycloalkyl, C3-7 cycloalkyl-Ci-6alkyl, C3-7 heterocycloalkyl, C3-7 heterocycloalkyl-C1-6 alkyl, C6-1oaryl, C6-1oaryl-C1-6alkyl, C3-9 heteroaryl, or C3-9heteroaryl-C1-6alkyl; and n and p are each, independently, integers from 1 to 10; and a pharmaceutically acceptable carrier, excipient, or diluent.

  治疗呼吸系统损伤或疾病的方法，包括：向需要治疗的病人施用包含通用公式I的化合物的药物组合物：或其盐、酯、溶剂化物、水合物或前药；其中：x是从1到10的整数；A和B各自独立为C3-7环烷基，C3-7环烷基-Ci-6烷基，C3-7杂环烷基，C3-7杂环烷基-C1-6烷基，C6-1o芳基，C6-1o芳基-C1-6烷基，C3-9杂芳基或C3-9杂芳基-C1-6烷基；n和p各自独立为从1到10的整数；以及药用可接受的载体、辅料或稀释剂。
• FBXO3 inhibitors
  申请人：University of Pittsburgh—Of the Commonwealth System of Higher Education

  公开号：US10307423B2

  公开（公告）日：2019-06-04

  A compound, or a pharmaceutically acceptable salt or ester thereof, having a structure of: wherein X is a divalent linking moiety; and R1-R10 are each individually H, optionally-substituted alkyl, optionally-substituted alkoxy, optionally-substituted aryl, optionally-substituted cycloalkyl, optionally-substituted heterocyclic, halogen, amino, or hydroxy, provided that at least one of R3 or R8 is an optionally-substituted alkyl, a substituted alkoxy, optionally-substituted aryl, optionally-substituted cycloalkyl, optionally-substituted heterocyclic, or halogen.

  一种化合物，或其药学上可接受的盐或酯，其结构为： 其中 X 是二价连接基团；以及 R1-R10 分别是 H、任选取代的烷基、任选取代的烷氧基、任选取代的芳基、任选取代的环烷基、任选取代的杂环基、卤素、氨基或羟基，但 R3 或 R8 中至少有一个是任选取代的烷基、取代的烷氧基、任选取代的芳基、任选取代的环烷基、任选取代的杂环基或卤素。
• Benzathine analogs
  申请人：University of Pittsburgh—Of the Commonwealth System of Higher Education

  公开号：US10369150B2

  公开（公告）日：2019-08-06

  A compound, or a pharmaceutically acceptable salt or ester thereof, having a structure of: wherein X is a divalent linking moiety; and R1-R10 are each individually H, optionally-substituted alkyl, optionally-substituted alkoxy, optionally-substituted aryl, optionally-substituted cycloalkyl, optionally-substituted heterocyclic, halogen, amino, or hydroxy, provided that at least one of R3 or R8 is an optionally-substituted alkyl, a substituted alkoxy, optionally-substituted aryl, optionally-substituted cycloalkyl, optionally-substituted heterocyclic, or halogen.

  一种化合物，或其药学上可接受的盐或酯，其结构为： 其中 X 是二价连接基团；以及 R1-R10 分别是 H、任选取代的烷基、任选取代的烷氧基、任选取代的芳基、任选取代的环烷基、任选取代的杂环基、卤素、氨基或羟基，但 R3 或 R8 中至少有一个是任选取代的烷基、取代的烷氧基、任选取代的芳基、任选取代的环烷基、任选取代的杂环基或卤素。
• FBXO3 INHIBITORS
  申请人：University of Pittsburgh - Of the Commonwealth System of Higher Education

  公开号：EP2858975B1

  公开（公告）日：2019-04-24
• BENZATHINE ANALOGS
  申请人：University of Pittsburgh - Of the Commonwealth System of Higher Education

  公开号：US20160237040A1

  公开（公告）日：2016-08-18

  A compound, or a pharmaceutically acceptable salt or ester thereof, having a structure of: wherein X is a divalent linking moiety; and R 1 -R 10 are each individually H, optionally-substituted alkyl, optionally-substituted alkoxy, optionally-substituted aryl, optionally-substituted cycloalkyl, optionally-substituted heterocyclic, halogen, amino, or hydroxy, provided that at least one of R 3 or R 8 is an optionally-substituted alkyl, a substituted alkoxy, optionally-substituted aryl, optionally-substituted cycloalkyl, optionally-substituted heterocyclic, or halogen.